HPV genotypes: implications for worldwide cervical cancer screening and vaccination

Abstract

In the Lancet Oncology today, Silvia de Sanjose and colleagues 1 de Sanjose S Quint WGV Alemany L et al. for the Retrospective International Survey and HPV Time Trends Study GroupHuman papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; (published online Oct 18.)https://doi.org/10.1016/S1470-2045(10)70230-8 Summary Full Text Full Text PDF PubMed Scopus (1753) Google Scholar report the results of an international prevalence survey about the human papillomavirus (HPV) type-specific burden of cervical cancer worldwide. The study included more than 10 000 histologically confirmed cases of invasive cervical cancer from 38 countries. Samples were pooled from large geographical regions and the number of institutions contributing cases was variable. For example, Australia represented all of Oceania (n=170 HPV-positive cases), and the USA represented all of North America (n=160 HPV-positive cases), with only one or two institutions, respectively, providing cases. Thus, some regional-specific and country-specific HPV prevalence estimates were limited and should not be considered in isolation. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyTo our knowledge, this study is the largest assessment of HPV genotypes to date. HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines. Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45. Full-Text PDF